Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy (LON:FARN) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Does the media favor FARN or OXB?

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 1 mentions for Oxford Biomedica. Faron Pharmaceuticals Oy's average media sentiment score of 0.93 beat Oxford Biomedica's score of 0.29 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer FARN or OXB?

Oxford Biomedica has a consensus target price of GBX 540.25, suggesting a potential downside of 6.53%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals & insiders hold more shares of FARN or OXB?

2.9% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 4.1% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility & risk, FARN or OXB?

Faron Pharmaceuticals Oy has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Is FARN or OXB more profitable?

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Oxford Biomedica's net margin of -145.98%. Faron Pharmaceuticals Oy's return on equity of 0.46% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	0.46%	-70.00%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Which has preferable valuation and earnings, FARN or OXB?

Faron Pharmaceuticals Oy has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£0.27	-703.70
Oxford Biomedica	£128.80M	5.39	-£143.51M	-£0.42	-1,384.43

Summary

Oxford Biomedica beats Faron Pharmaceuticals Oy on 8 of the 15 factors compared between the two stocks.